TrialFrontiers in immunology2026

Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial.

Zhiqiang Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.